Gene

EGFR

epidermal growth factor receptor

Explore in graph →CI-GENE-00044375HGNC:3236 ENSG00000146648 NCBI 1956 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (644)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 451–500 of 644 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
EGFR N826Y1
Gefitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Does Not Support Sensitivity Response	2

Cohorts

Alteration frequency by cohort (195)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved195 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
BRAF Fusions - IMPACT Clinical Sequencing Cohort (MSK, Clin Cancer Res 2024) braf_msk_impact_2024	unmapped	Ssm	10

Literature

Linked publications (141)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 141 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

EGFR T790M resistance mutation in non small-cell lung carcinoma.
· Clin Chim Acta · 2015 · PMID 25668228 · validated civic_curation pubmed
Osimertinib: First Global Approval.
· Drugs · 2016 · PMID 26729184 · validated civic_curation pubmed
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
· N Engl J Med · 2017 · PMID 27959700 · validated civic_curation pubmed
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
· Oncologist · 2014 · PMID 24868098 · validated civic_curation

EGFR Overexpression15
(prognostic)	Brain GlioblastomaALIAS	Prognostic	B	Supports Poor Outcome	3	accepted	EID474 In patients with glioblastoma multiforme, those with overespression of wild-type EGFR had shorter overall survival. PMID 14583498 · Shinojima et al., 2003 · Open in CIViC	civic
〃	Head and Neck Squamous Cell Carcinoma	Prognostic	B	Supports Poor Outcome	3	accepted	EID782 Primary tumors of 91 patients with head and neck squamous cell carcinoma were analyzed for expression of EGFR and TGF-alpha using IHC. Expression of EGFR or TGF-alpha were associated with reduced dise… (full text at CIViC) PMID 9625170 · Rubin Grandis et al., 1998 · Open in CIViC	civic
〃	Esophageal Squamous Cell CarcinomaALIAS	Prognostic	B	Supports Poor Outcome	3	accepted	EID784 55 tumor samples were analyzed for EGFR expression using IHC. PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8 ± 0.5 … (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC	civic
Unspecified therapy	Esophageal Squamous Cell CarcinomaALIAS	Predictive	B	Does Not Support Sensitivity Response	3	rejected	EID833 Expression of EGFR in 55 samples of esophageal squamous cell carcinoma with IHC was not predictive of response to EGFR inhibitor nimotuzumab. EGFR overexpression was related to poor OS and PFS. PMID 26459251 · Jia et al., 2016 · Open in CIViC	civic
(prognostic)	Esophageal Squamous Cell CarcinomaALIAS	Prognostic	B	Supports Poor Outcome	3	rejected	EID834 Overexpression of EGFR in 55 samples of esophageal squamous cell carcinoma as assesesed by IHC, was related to poor OS and PFS (PFS: 5.8 ± 0.5 vs. 11.0 ± 2.8 months, P = 0.007; OS: 9.7 ± 0.5 vs. 21.5… (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC	civic
Bevacizumab + LomustineCombination	GlioblastomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	submitted	EID10894 "Classical" glioblastoma patients (referred to as group IGS-18) exhibited overexpression of EGFR and showed improved survival with combination therapy of bevacizumab and lomustine with a median OS 11.… (full text at CIViC) PMID 26762204 · Erdem-Eraslan et al., 2016 · Open in CIViC	civic
Cetuximab	Head and Neck Squamous Cell Carcinoma	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID692 EGFR expression level was not predicitive of response to cetuximab-containing first line regimens in recurrent or metastatic head and neck squamous cell carcinoma and KRAS-wild type colorectal carcino… (full text at CIViC) PMID 23265711 · Licitra et al., 2013 · Open in CIViC	civic
Cetuximab + DocetaxelCombination	Head and Neck Squamous Cell Carcinoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID849 47 HNSCC patients treated with cetuximab/docetaxel were retrospectively analyzed for EGFRvIII, EGFR and AREG expression with IHC. 73 % of cases expressed high level of EGFR. EGFR expression had no imp… (full text at CIViC) PMID 21653686 · Tinhofer et al., 2011 · Open in CIViC	civic
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID693 EGFR overexpression was correlated with longer overall survival in patients with advanced NSCLC treated with first line chemotherapy and cetuximab than those treated with first line chemotherapy alone… (full text at CIViC) PMID 22056021 · Pirker et al., 2012 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID737 In this prospective study in 37 patients of whom 34 were treated with different EGFR inhibitors (gefitinib, erlotinib, afatinib), EGFR mutations and a higher relative expression of EGFR in comparison … (full text at CIViC) PMID 26439803 · Park et al., 2015 · Open in CIViC	civic
Erlotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID5827 A total of 57 patients with HER1/EGFR positive non-small cell lung cancer were treated with erlotinib therapy. Two patients achieved a complete response, five had a partial response, and 22/57 patient… (full text at CIViC) PMID 15310767 · Pérez-Soler et al., 2004 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	—	submitted	EID3797 A phase 3 study of 889 advanced non-small cell lung cancer patients (with non-progressive disease while on standard chemotherapy treatment), reported that patients harboring EGFR mutation (exon 19 del… (full text at CIViC) PMID 21969500 · Brugger et al., 2011 · Open in CIViC	civic
Gefitinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID954 82 patients treated with gefitinib were retrospectively analyzed for EGFR mRNA expression (rt-PCR in 64 patients). Patients with high EGFR mRNA expression (>5.01) had 43% response probability, whereas… (full text at CIViC) PMID 16707605 · Dziadziuszko et al., 2006 · Open in CIViC	civic
Gefitinib + Radiation TherapyCombination	Glioma	Predictive	D	Supports Sensitivity Response	3	submitted	EID7803 Study of malignant glioma cells with EGFR amplification, IGRG88. IGRG88 cells showed a 946 fold increase of EGFR mRNA when compared to IGRG119, a tumor known to express low levels of EGFR mRNA. IHC … (full text at CIViC) PMID 18386816 · Geoerger et al., 2008 · Open in CIViC	civic
Nimotuzumab	Esophageal Squamous Cell CarcinomaALIAS	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID783 55 tumor samples were analyzed for EGFR expression using IHC. The objective response rate to anti-EGFR antibody nimotuzumab did not differ significantly between EGFR high- (18 pts) and EGFR low to mod… (full text at CIViC) PMID 26459251 · Jia et al., 2016 · Open in CIViC	civic

EGFR Overexpression + KRAS MutationEGFR KRAS3
Cetuximab	Colorectal Adenocarcinoma	Predictive	B	Supports Adverse Response	3	submitted	EID11059 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC	civic
(prognostic)	Colorectal Adenocarcinoma	Prognostic	B	Supports Poor Outcome	3	submitted	EID11058 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC	civic
Cetuximab + ChemotherapyCombination	Colorectal Adenocarcinoma	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11062 The Medical Research Council (MRC) COIN trial consisted of patients with histologically confirmed adenocarcinoma of the colon or rectum, inoperable metastatic or locoregional measurable disease, and w… (full text at CIViC) PMID 21641636 · Maughan et al., 2011 · Open in CIViC	civic

EGFR P596L3
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID9640 Ba/F3 cells transfected with EGFR P596L had levels of p-EGFR, p-STAT5, and p-AKT that were similar to known activating mutation L858R and higher than in cells expressing wild-type EGFR. PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	3	submitted	EID9648 The oncogenic potential of somatic EGFR mutations found in colorectal cancer samples were tested. IL-3 independent growth of Ba/F3 cells was achieved when cells were transduced with EGFR P596L. NIH-3T… (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID9658 Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR P596L showed a dose-dependent … (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic

EGFR R165Q3
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID9595 Ba/F3 cells transfected with EGFR R165Q had levels of p-EGFR, p-STAT5, and p-AKT that were similar to known activating mutation L858R and higher than in cells expressing wild-type EGFR. PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	3	submitted	EID9596 The oncogenic potential of somatic EGFR mutations found in colorectal cancer samples were tested. IL-3 independent growth of Ba/F3 cells was achieved when cells were transduced with EGFR R165Q. NIH-3T… (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	submitted	EID9597 Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR R165Q showed a dose-dependent … (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic

EGFR R222C4
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	3	submitted	EID9638 Ba/F3 cells transfected with EGFR R222C had levels of p-EGFR, p-STAT5, and p-AKT that were similar to known activating mutation L858R and higher than in cells expressing wild-type EGFR. PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
(oncogenic)	Malignant NeoplasmALIAS	Oncogenic	D	Supports Oncogenicity	3	submitted	EID9646 The oncogenic potential of somatic EGFR mutations found in colorectal cancer samples were tested. IL-3 independent growth of Ba/F3 cells was achieved when cells were transduced with EGFR R222C. NIH-3T… (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic
(functional)	—UNRESOLVED	Functional	D	Supports Gain Of Function	2	accepted	EID9333 A moderate throughput platform was used to functionally characterize 1000 somatic cancer variants. The platform found EGFR R222C to be an activating mutation based on in vitro screening in two growth-… (full text at CIViC) PMID 29533785 · Ng et al., 2018 · Open in CIViC	civic
Cetuximab + PanitumumabSubstitutes	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	submitted	EID9655 Oncogenic somatic EGFR mutations found in colorectal cancer samples were tested for sensitivity to EGFR inhibitors cetuximab and panitumumab. Ba/F3 cells expressing EGFR R222C showed a dose-dependent … (full text at CIViC) PMID 31290142 · Kim et al., 2020 · Open in CIViC	civic

EGFR Rare Exon 18-21 Mutation2
Erlotinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID4755 In a cohort of NSCLC patients treated with tyrosine kinase inhibitors erlotinib or gefitinib, 61 patients with uncommon mutations of unknown clinical significance (UMUCS) in EGFR exons 18-21 responded… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC	civic
〃	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	2	accepted	EID4762 In a cohort of NSCLC patients tested for mutation in EGFR exons 18-21 a subset had uncommon mutations of unknown clinical significance (UMUCS). The most commonly occurring UMUCS were G719 and L861 mut… (full text at CIViC) PMID 21531810 · Wu et al., 2011 · Open in CIViC	civic